NEUK203-215
/ Neukio Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 28, 2025
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=8 | Recruiting | Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd.
New P1 trial • Immunology
1 to 1
Of
1
Go to page
1